middle.news
Telix Scores Regulatory Nod to Bring Illuccix Prostate Imaging to China
8:36am on Tuesday 20th of January, 2026 AEDT
•
Healthcare
Read Story
Telix Scores Regulatory Nod to Bring Illuccix Prostate Imaging to China
8:36am on Tuesday 20th of January, 2026 AEDT
Key Points
NMPA accepts Illuccix NDA for prostate cancer imaging in China
Phase 3 trial shows 94.8% positive predictive value in Chinese patients
Over two-thirds of patients had treatment plans changed based on imaging
Illuccix already approved in US, Australia, Canada, Europe and more
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Telix Pharmaceuticals (ASX:TLX)
OPEN ARTICLE